Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-28
2006-03-28
Richter, Johnn (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S229200, C514S249000, C514S211070, C540S463000
Reexamination Certificate
active
07018999
ABSTRACT:
Novel methods for the treatment and/or prevention of pain are presented. The methods may comprise administering to a subject in need thereof an effective amount of a stress-activated protein kinase inhibitor. Preferred compounds for use in the methods include fused pyrrolocarbazole compounds.
REFERENCES:
patent: 1381031 (1921-06-01), Thompson
patent: 4877776 (1989-10-01), Murakata et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5093330 (1992-03-01), Caravatti et al.
patent: 5468872 (1995-11-01), Glicksman et al.
patent: 5516771 (1996-05-01), Dionne et al.
patent: 5534426 (1996-07-01), Karin et al.
patent: 5593884 (1997-01-01), Karin et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5599808 (1997-02-01), Goldstein et al.
patent: 5605808 (1997-02-01), Karin et al.
patent: 5616724 (1997-04-01), Hudkins et al.
patent: 5621101 (1997-04-01), Lewis et al.
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 5756494 (1998-05-01), Lewis et al.
patent: 6046208 (2000-04-01), Adams et al.
patent: 6093713 (2000-07-01), Hudkins et al.
patent: 6127401 (2000-10-01), Singh et al.
patent: 6306849 (2001-10-01), Hudkins et al.
patent: 6399780 (2002-06-01), Hudkins
patent: 2 337 702 (1999-12-01), None
patent: WO 93/08809 (1993-05-01), None
patent: WO 95/03324 (1995-02-01), None
patent: WO 97/49406 (1997-12-01), None
patent: WO 99/53927 (1999-10-01), None
patent: WO 99/58982 (1999-11-01), None
patent: WO 00/06563 (2000-02-01), None
patent: WO 00/13015 (2000-03-01), None
patent: WO 00/35906 (2000-06-01), None
patent: WO 00/35909 (2000-06-01), None
patent: WO 00/35921 (2000-06-01), None
patent: WO 00/47583 (2000-08-01), None
patent: WO 00/64872 (2000-11-01), None
patent: WO 00/75118 (2000-12-01), None
patent: WO 01/01986 (2001-01-01), None
patent: WO 01/05390 (2001-01-01), None
patent: WO 01/12609 (2001-02-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/14380 (2001-03-01), None
patent: WO 01/91749 (2001-12-01), None
patent: WO 02/38035 (2002-05-01), None
patent: WO 02/46184 (2002-06-01), None
Glicksman et al., CEP-1347/KT7515 Prevents Motor Neuronal Programmed Cell Death and Injury-Induced Dedifferentiation In Vivo, J. Neurobiol. 35, 361-378, 1998.
Borasio et al., CEP-1347/KT7515, a JNK partway inhibitor, supports the in vivo survival of chick embryonic neurons, NeuroReport 9, 1435-1439, 1998.
Saporito et al., CEP-1347/KT-7514, an Inhibitor of c-jun N-Terminal Kinase Activation, The American Society for Pharmacology and Experimental Therapeutics, TPET 288: 421-427, 1999.
Wagner et al., CEP-1374 Inhibits Caerulein-Induced Rat Pancreatic JNK Actiation and Ameliorates Caerulein Pancreatitis, Am. J. Physiol. Gastrointest. Liver Physiol. 278: G165-G172, 2000.
Bennet et al., “SP600125, a selective inhibitor of JNK that modulates the activation and differentiation of CD4+ cells”, Inflammation Research, vol. 49, No. Supplement 2, 2000, p. S102 (abstract).
Bodner et al., “CEP-1347/KT7515 rescues rat dorsal root ganglia from gp 120IIIB-induced apoptosis”, Society for Neuroscience Abstracts, vol. 26, No. 1-2, 2000 (abstract).
Clerk et al., “The p38-MAPK inhibitor, SB203580 inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs)”, FEBS Letters, Elsevier Science Publishers, Ambsterdam, NL, vl. 426, No. 1, 1998, pp. 93-96.
Forrer et al., “Enzyme-linked immunosorbent assay for measurement of JNK, ERK<and p38 kinase activities”, Biological Chemistry, vol. 379, No. 8-9, 1998, pp. 1101-1111.
Beers, M.H.,The Merck Manual of Diagnosis&Therapy, 1999, Merck Research Laboratories, New York, USA, XP002214785, p. 1491, col. 2, paragraph 5; p. 1496, col. 2, paragraph 3.
Brenner, B. et al.,The Journal of Biological Chemistry, 1997, 272(35), 22173-22181.
Chapman, C.R. et al.,Pain, 1990, 43, 47-55.
Galer, B.S. et al,Pain, 1992, 49, 87-91.
Guan, Z. et al.,The Journal of Biological Chemistry, 1997, 272(12), 8083-8089.
Hai, T. et al.,Gene Expression, 1999, 7, 321-335.
Kramer, R.M. et al.,The Journal of Biological Chemistry, 1996, 271(44), 27723-27729.
Kyriakis, J.M. et al.,BioEssays, 1996, 18(7), 567-577.
Lin, L. et al.,Cell, 1993, 72, 269-278.
Maroney, A.C., et al.,The Journal of Neuroscience, 1998, 18(1), 104-111.
Nakanishi, O. et al.,Cellular and Molecular Neurobiology, 1999, 19(2), 191-197.
Portenoy, R.K. et al.,Pain, 1990, 43, 273-286.
Xia, Z. et al.,Science, 1995, 270, 1326-1331.
Xie, W. et al.,The Journal of Biological Chemistry, 1995, 270(46), 27622-27628.
Xie, W. et al.,Molecular and Cellular Biology, 1994, 14(10), 6531-6539.
Aimone Lisa D.
Hudkins Robert L.
Miller Matthew S.
Cephalon Inc.
Hrubiec Robert T.
Larsen Scott K.
Nwaonicha Chukwuma
Richter Johnn
LandOfFree
Methods for the treatment and prevention of pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment and prevention of pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment and prevention of pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543783